#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,¹ Gomella LG,² Sharma P,³ Plimack ER,⁴ O’Donnell PH,⁵ Hoffman-Censits J,² Flaig TW,⁶ Quinn DI,⁷ Campogan D,⁸ Haynes H,⁸ McCoy C,⁸ Maher J,⁸ DeVries T,⁸ Sheikh N,⁸ and Lerner SP⁹ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ²Jefferson Medical College and Kimmel Cancer Center, Philadelphia, PA, USA; ³University of Texas MD Anderson Cancer Center, Houston, TX, USA; ⁴Fox Chase Cancer Center, Philadelphia, PA, USA; ⁵The University of Chicago, Chicago, IL, USA; ⁶University of Colorado, Denver, CO, USA; ⁷University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; ⁸Dendreon Corporation, Seattle, WA, USA; ⁹Baylor College of Medicine, The Scott Department of Urology, Houston, TX, USA